{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:21:53Z","timestamp":1791397313179,"version":"4.3.3"},"reference-count":196,"publisher":"Elsevier","isbn-type":[{"value":"9780128209936","type":"print"}],"license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000923","name":"Australian Research Council","doi-asserted-by":"publisher","award":["DP170104431"],"award-info":[{"award-number":["DP170104431"]}],"id":[{"id":"10.13039\/501100000923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001794","name":"University of Queensland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013927","name":"National MPS Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013927","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1016\/bs.accb.2019.09.001","type":"book-chapter","created":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T09:01:14Z","timestamp":1601283674000},"page":"71-117","source":"Crossref","is-referenced-by-count":33,"title":["Mucopolysaccharidosis type II (Hunter syndrome): Clinical and biochemical aspects of the disease and approaches to its diagnosis and treatment"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.accb.2019.09.001_bb0010","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/nrneurol.2013.163","article-title":"Lysosomal Storage Diseases\u2014The Horizon Expands","volume":"9","author":"Boustany","year":"2013","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/bs.accb.2019.09.001_bb0015","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1365-2141.2004.05293.x","article-title":"Lysosomal Storage Disorders","volume":"128","author":"Vellodi","year":"2005","journal-title":"Br. J. Haematol."},{"key":"10.1016\/bs.accb.2019.09.001_bb0020","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.bbamcr.2008.12.001","article-title":"Lysosomal Disorders: From Storage to Cellular Damage","volume":"1793","author":"Ballabio","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/bs.accb.2019.09.001_bb0025","series-title":"Lysosomal Storage Disorders","first-page":"37","article-title":"Classification of Lysosomal Storage Diseases","author":"Winchester","year":"2012"},{"key":"10.1016\/bs.accb.2019.09.001_bb0030","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1517\/14728214.2010.498580","article-title":"Emerging Drugs for Lysosomal Storage Diseases","volume":"15","author":"Beck","year":"2010","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/bs.accb.2019.09.001_bb0035","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s004399900075","article-title":"The Frequency of Lysosomal Storage Diseases in The Netherlands","volume":"105","author":"Poorthuis","year":"1999","journal-title":"Hum. Genet."},{"key":"10.1016\/bs.accb.2019.09.001_bb0040","first-page":"249","article-title":"Prevalence of Lysosomal Storage Disorders","volume":"281","author":"Meikle","year":"1999","journal-title":"J. Am. Med. Soc."},{"key":"10.1016\/bs.accb.2019.09.001_bb0045","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1097\/MOP.0b013e3282f161f2","article-title":"Enzyme Reconstitution\/Replacement Therapy for Lysosomal Storage Diseases","volume":"19","author":"Burrow","year":"2007","journal-title":"Curr. Opin. Pediatr."},{"key":"10.1016\/bs.accb.2019.09.001_bb0050","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.spen.2008.05.005","article-title":"Current Strategies in the Management of Lysosomal Storage Diseases","volume":"15","author":"Heese","year":"2008","journal-title":"Semin. Pediatr. Neurol."},{"key":"10.1016\/bs.accb.2019.09.001_bb0055","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.bbamcr.2008.08.009","article-title":"Treating Lysosomal Storage Disorders: Current Practice and Future Prospects","volume":"1793","author":"Platt","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/bs.accb.2019.09.001_bb0060","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1042\/BST0381465","article-title":"Treatments for Lysosomal Storage Disorders","volume":"38","author":"Lachmann","year":"2010","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/bs.accb.2019.09.001_bb0065","first-page":"1082","article-title":"Lysosomal Storage Disorders and Treatment","volume":"2","author":"Murthy","year":"2010","journal-title":"Int. J. PharmTech Res."},{"key":"10.1016\/bs.accb.2019.09.001_bb0070","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1177\/2042018810384429","article-title":"Therapeutic Approaches for Lysosomal Storage Diseases","volume":"1","author":"Pastores","year":"2010","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"10.1016\/bs.accb.2019.09.001_bb0075","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2174\/1872214808666140115111350","article-title":"Treatment of Lysosomal Storage Diseases: Recent Patents and Future Strategies","volume":"8","author":"Ortolano","year":"2014","journal-title":"Recent Pat. Endocr. Metab. Immune Drug Discov."},{"key":"10.1016\/bs.accb.2019.09.001_bb0080","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ymgme.2013.06.007","article-title":"Newborn Screening and Diagnosis of Mucopolysaccharidoses","volume":"110","author":"Tomatsu","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/bs.accb.2019.09.001_bb0085","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.beem.2014.08.004","article-title":"Epidemiology and Diagnosis of Lysosomal Storage Disorders; Challenges of Screening","volume":"29","author":"Kingma","year":"2015","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"10.1016\/bs.accb.2019.09.001_bb0090","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1747-0285.2008.00741.x","article-title":"The Structure of Glycosaminoglycans and Their Interactions With Proteins","volume":"72","author":"Gandhi","year":"2008","journal-title":"Chem. Biol. Drug. Des."},{"key":"10.1016\/bs.accb.2019.09.001_bb0095","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1039\/b100916h","article-title":"Heparin and Heparan Sulfate: Structure and Function","volume":"19","author":"Rabenstein","year":"2002","journal-title":"Nat. Prod. Rep."},{"key":"10.1016\/bs.accb.2019.09.001_bb0100","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/00005792-196511000-00001","article-title":"The Genetic Mucopolysaccharidoses","volume":"44","author":"McKusick","year":"1965","journal-title":"Medicine"},{"key":"10.1016\/bs.accb.2019.09.001_bb0105","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1073\/pnas.73.2.630","article-title":"The Mucopolysaccharidoses (A Review)","volume":"73","author":"Dorfman","year":"1976","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.accb.2019.09.001_bb0110","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/471325","article-title":"Glycosaminoglycan Storage Disorders: A Review","volume":"2012","author":"Coutinho","year":"2012","journal-title":"Biochem. Res. Int."},{"key":"10.1016\/bs.accb.2019.09.001_bb0115","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1017\/S1462399408000550","article-title":"The Mucopolysaccharidoses: A Success of Molecular Medicine","volume":"10","author":"Clarke","year":"2008","journal-title":"Expert Rev. Mol. Med."},{"key":"10.1016\/bs.accb.2019.09.001_bb0120","doi-asserted-by":"crossref","first-page":"v4","DOI":"10.1093\/rheumatology\/ker394","article-title":"Overview of the Mucopolysaccharidoses","volume":"50","author":"Muenzer","year":"2011","journal-title":"Rheumatology"},{"key":"10.1016\/bs.accb.2019.09.001_bb0125","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s11926-013-0389-0","article-title":"Mucopolysaccharidoses","volume":"16","author":"Cimaz","year":"2014","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/bs.accb.2019.09.001_bb0130","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1590\/S1415-47572012000600006","article-title":"Mucopolysacccharidoses: From Understanding to Treatment, a Century of Discoveries","volume":"35","author":"Giugliani","year":"2012","journal-title":"Genet. Mol. Biol."},{"key":"10.1016\/bs.accb.2019.09.001_bb0135","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/j.jpeds.2004.01.052","article-title":"The Mucopolysaccharidoses: A Heterogeneous Group of Disorders With Variable Pediatric Presentations","volume":"144","author":"Muenzer","year":"2004","journal-title":"J. Pediatr."},{"key":"10.1016\/bs.accb.2019.09.001_bb0140","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00431-007-0635-4","article-title":"Mucopolysaccharidosis Type II (Hunter Syndrome): A Clinical Review and Recommendations for Treatment in the Era of Enzyme Replacement Therapy","volume":"167","author":"Wraith","year":"2008","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/bs.accb.2019.09.001_bb0145","doi-asserted-by":"crossref","first-page":"861","DOI":"10.2174\/138920111795542714","article-title":"Mucopolysaccharidosis Type II (Hunter Syndrome): Clinical Picture and Treatment","volume":"12","author":"Beck","year":"2011","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/bs.accb.2019.09.001_bb0150","first-page":"104","article-title":"A Rare Disease in Two Brothers","volume":"10","author":"Hunter","year":"1917","journal-title":"Proc. R. Soc. Med."},{"key":"10.1016\/bs.accb.2019.09.001_bb0155","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/BF02222956","article-title":"\u00dcber Einen Typ Multipler Abartungen, Vorwiegend am Skelettsystem","volume":"24","author":"Hurler","year":"1920","journal-title":"Z. Kinderheilkd."},{"key":"10.1016\/bs.accb.2019.09.001_bb0160","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3928\/00904481-19780201-06","article-title":"The Mucopolysaccharidoses: Advances in Understanding and Treatment","volume":"7","author":"Lorincz","year":"1978","journal-title":"Pediatr. Ann."},{"key":"10.1016\/bs.accb.2019.09.001_bb0165","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3109\/00365515209060631","article-title":"Gargoylism\u2014A Mucopolysaccharidosis","volume":"4","author":"Brante","year":"1952","journal-title":"Scand. J. Clin. Lab. Invest."},{"key":"10.1016\/bs.accb.2019.09.001_bb0170","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1073\/pnas.43.6.443","article-title":"Occurrence of Urinary Acid Mucopolysaccharides in the Hurler Syndrome","volume":"43","author":"Dorfman","year":"1957","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.accb.2019.09.001_bb0175","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1073\/pnas.60.2.699","article-title":"The Defect in Hurler's and Hunter's Syndromes: Faulty Degradation of Mucopolysaccharide","volume":"60","author":"Fratantoni","year":"1968","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.accb.2019.09.001_bb0180","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1073\/pnas.64.1.360","article-title":"The Defect in Hurler and Hunter Syndromes, II. Deficiency of Specific Factors Involved in Mucopolysaccharide Degradation","volume":"64","author":"Fratantoni","year":"1969","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.accb.2019.09.001_bb0185","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.1749-6632.1971.tb46934.x","article-title":"Corrective Factors for Inborn Errors of Mucopolysaccharide Metabolism","volume":"179","author":"Neufeld","year":"1971","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/bs.accb.2019.09.001_bb0190","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/0006-291X(70)90414-6","article-title":"Characterization of the Factor Deficient in the Hunter Syndrome by Polyacrylamide Gel Electrophoresis","volume":"39","author":"Cantz","year":"1970","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/bs.accb.2019.09.001_bb0195","doi-asserted-by":"crossref","first-page":"5456","DOI":"10.1016\/S0021-9258(20)81127-2","article-title":"The Hunter Corrective Factor: Purification and Preliminary Characterization","volume":"247","author":"Cantz","year":"1972","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.accb.2019.09.001_bb0200","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1073\/pnas.70.7.2134","article-title":"The Defect in the Hunter Syndrome: Deficiency of Sulfoiduronate Sulfatase","volume":"70","author":"Bach","year":"1973","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.accb.2019.09.001_bb0205","doi-asserted-by":"crossref","first-page":"8531","DOI":"10.1073\/pnas.87.21.8531","article-title":"Hunter Syndrome: Isolation of an Iduronate-2-Sulfatase cDNA Clone and Analysis of Patient DNA","volume":"87","author":"Wilson","year":"1990","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.accb.2019.09.001_bb0210","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/BF00194643","article-title":"Frequent Deletions at Xq28 Indicate Genetic Heterogeneity in Hunter Syndrome","volume":"86","author":"Wilson","year":"1991","journal-title":"Hum. Genet."},{"key":"10.1016\/bs.accb.2019.09.001_bb0215","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/hmg\/2.1.5","article-title":"Determination of the Organisation of Coding Sequences Within the Iduronate Sulphate Sulphatase (IDS) Gene","volume":"2","author":"Flomen","year":"1993","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/bs.accb.2019.09.001_bb0220","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1006\/geno.1993.1406","article-title":"Sequence of the Human Iduronate 2-Sulfatase (IDS) Gene","volume":"17","author":"Wilson","year":"1993","journal-title":"Genomics"},{"key":"10.1016\/bs.accb.2019.09.001_bb0230","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/humu.10212","article-title":"Human Gene Mutation Database (HGMD\u00ae): 2003 Update","volume":"21","author":"Stenson","year":"2003","journal-title":"Hum. Mutat."},{"key":"10.1016\/bs.accb.2019.09.001_bb0235","first-page":"1202","article-title":"Mucopolysaccharidosis Type II (Hunter Syndrome): Mutation \"Hot Spots\" in the Iduronate-2-Sulfatase Gene","volume":"59","author":"Rathmann","year":"1996","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/bs.accb.2019.09.001_bb0240","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/humu.1169","article-title":"Molecular Analysis of 40 Italian Patients With Mucopolysaccharidosis Type II: New Mutations in the Iduronate-2-Sulfatase (IDS) Gene","volume":"18","author":"Filocamo","year":"2001","journal-title":"Hum. Mutat."},{"key":"10.1016\/bs.accb.2019.09.001_bb0245","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1651-2227.2002.tb03116.x","article-title":"Mucopolysaccharidosis Type II\u2014Genotype\/Phenotype Aspects","volume":"91","author":"Froissart","year":"2002","journal-title":"Acta Paediatr."},{"key":"10.1016\/bs.accb.2019.09.001_bb0250","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/humu.9128","article-title":"Mutational Spectrum of the Iduronate-2-Sulfatase Gene in 25 Unrelated Korean Hunter Syndrome Patients: Identification of 13 Novel Mutations","volume":"21","author":"Kim","year":"2003","journal-title":"Hum. Mutat."},{"key":"10.1016\/bs.accb.2019.09.001_bb0255","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/ajmg.a.10215","article-title":"Expression Studies of Two Novel in CIS-mutations Identified in an Intermediate Case of Hunter Syndrome","volume":"120A","author":"Ricci","year":"2003","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/bs.accb.2019.09.001_bb0260","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s10038-005-0266-4","article-title":"Mutational and Structural Analysis of Japanese Patients With Mucopolysaccharidosis Type II","volume":"50","author":"Kato","year":"2005","journal-title":"J. Hum. Genet."},{"key":"10.1016\/bs.accb.2019.09.001_bb0265","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s10545-006-0440-7","article-title":"Effect of Hunter Disease (Mucopolysaccharidosis Type II) Mutations on Molecular Phenotypes of Iduronate-2-Sulfatase: Enzymatic Activity, Protein Processing and Structural Analysis","volume":"29","author":"Sukegawa-Hayasaka","year":"2006","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/bs.accb.2019.09.001_bb0270","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1651-2227.2007.00213.x","article-title":"Mucopolysaccharidosis Type II: An Update on Mutation Spectrum","volume":"96","author":"Froissart","year":"2007","journal-title":"Acta Paediatr."},{"key":"10.1016\/bs.accb.2019.09.001_bb0275","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1746-1596-6-42","article-title":"Molecular Analysis of Iduronate-2-Sulfatase Gene in Tunisian Patients With Mucopolysaccharidosis Type II","volume":"6","author":"Chkioua","year":"2011","journal-title":"Diagn. Pathol."},{"key":"10.1016\/bs.accb.2019.09.001_bb0280","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.gene.2013.06.084","article-title":"A 3\u2032 Splice Site Mutation of IDS Gene in a Chinese Family With Mucopolysaccharidosis Type II","volume":"528","author":"Jin","year":"2013","journal-title":"Gene"},{"key":"10.1016\/bs.accb.2019.09.001_bb0285","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ymgme.2013.08.011","article-title":"Mucopolysaccharidosis Type II: Identification of 30 Novel Mutations Among Latin American Patients","volume":"111","author":"Brusius-Facchin","year":"2014","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/bs.accb.2019.09.001_bb0290","series-title":"Advances in Computational Biology. Advances in Intelligent Systems and Computing","first-page":"205","article-title":"In Silico Analysis of Iduronate 2 Sulfatase Mutations in Colombian Patients With Hunter Syndrome (MPSII)","volume":"Vol. 232","author":"Galvis","year":"2014"},{"key":"10.1016\/bs.accb.2019.09.001_bb0295","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.pediatrneurol.2004.10.009","article-title":"Mucopolysaccharidosis Type II in Females: Case Report and Review of Literature","volume":"32","author":"Tuschl","year":"2005","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/bs.accb.2019.09.001_bb0300","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/ajmg.a.34415","article-title":"Mucopolysaccharidosis Type II in Females and Response to Enzyme Replacement Therapy","volume":"158A","author":"Jurecka","year":"2012","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/bs.accb.2019.09.001_bb0305","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1002\/ajmg.a.36667","article-title":"Mucopolysaccharidosis Type II in a Female Patient With a Reciprocal X;9 Translocation and Skewed X Chromosome Inactivation","volume":"164","author":"Lonardo","year":"2014","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/bs.accb.2019.09.001_bb0310","series-title":"GeneReviews\u00ae [Internet]","article-title":"Mucopolysaccharidosis Type II","author":"Scarpa","year":"2007"},{"key":"10.1016\/bs.accb.2019.09.001_bb0315","doi-asserted-by":"crossref","first-page":"e377","DOI":"10.1542\/peds.2007-1350","article-title":"Recognition and Diagnosis of Mucopolysaccharidosis II (Hunter Syndrome)","volume":"121","author":"Martin","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/bs.accb.2019.09.001_bb0320","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/1750-1172-8-101","article-title":"The Impact of Hunter Syndrome (Mucopolysaccharidosis Type II) on Health-Related Quality of Life","volume":"8","author":"Raluy-Callado","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/bs.accb.2019.09.001_bb0325","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/s10545-009-1119-7","article-title":"Mortality and Cause of Death in Mucopolysaccharidosis Type II\u2014A Historical Review Based on Data From the Hunter Outcome Survey (HOS)","volume":"32","author":"Jones","year":"2009","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/bs.accb.2019.09.001_bb0330","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1469-8749.1983.tb13794.x","article-title":"The Natural History of the Severe Form of Hunter's Syndrome: A Study Based on 52 Cases","volume":"25","author":"Young","year":"1983","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/bs.accb.2019.09.001_bb0335","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1750-1172-6-72","article-title":"Mucopolysaccharidosis Type II: European Recommendations for the Diagnosis and Multidisciplinary Management of a Rare Disease","volume":"6","author":"Scarpa","year":"2011","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/bs.accb.2019.09.001_bb0340","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1136\/jmg.19.6.408","article-title":"A Clinical and Genetic Study of Hunter's Syndrome. 2 Differences Between the Mild and Severe Forms","volume":"19","author":"Young","year":"1982","journal-title":"J. Med. Genet."},{"key":"10.1016\/bs.accb.2019.09.001_bb0345","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1136\/adc.57.11.828","article-title":"Mild Form of Hunter's Syndrome: Clinical Delineation Based on 31 Cases","volume":"57","author":"Young","year":"1982","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/bs.accb.2019.09.001_bb0350","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13023-015-0259-0","article-title":"Diagnosis, Quality of Life, and Treatment of Patients With Hunter Syndrome in the French Healthcare System: A Retrospective Observational Study","volume":"10","author":"Guffon","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/bs.accb.2019.09.001_bb0355","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1365-2214.1981.tb00838.x","article-title":"Psychosocial Problems in Hunter's Syndrome","volume":"7","author":"Young","year":"1981","journal-title":"Child Care Health Dev."},{"key":"10.1016\/bs.accb.2019.09.001_bb0360","first-page":"e16","article-title":"Orthopedic Manifestations in Patients With Mucopolysaccharidosis Type II (Hunter Syndrome) Enrolled in the Hunter Outcome Survey","volume":"2","author":"Link","year":"2010","journal-title":"Orthop. Rev."},{"key":"10.1016\/bs.accb.2019.09.001_bb0365","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/01202412-199504010-00018","article-title":"Hunter's Syndrome as a Cause of Childhood Carpal Tunnel Syndrome: A Report of Three Cases","volume":"4","author":"Norman-Tyler","year":"1995","journal-title":"J. Pediatr. Orthop. B"},{"key":"10.1016\/bs.accb.2019.09.001_bb0370","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1001\/archopht.1967.00980020505013","article-title":"Ocular Histopathology in Hunter's Syndrome: Systemic Mucopolysaccharidosis Type II","volume":"77","author":"Goldberg","year":"1967","journal-title":"Archiv. Ophthalmol."},{"key":"10.1016\/bs.accb.2019.09.001_bb0375","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/archopht.1971.01000010166009","article-title":"Ultrastructural Ocular Pathology of Hunter's Syndrome: Systemic Mucopolysaccharidosis Type II","volume":"86","author":"Topping","year":"1971","journal-title":"Archiv. Ophthalmol."},{"key":"10.1016\/bs.accb.2019.09.001_bb0380","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.survophthal.2005.11.007","article-title":"Mucopolysaccharidoses and the Eye","volume":"51","author":"Ashworth","year":"2006","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/bs.accb.2019.09.001_bb0385","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3341\/kjo.2016.30.2.151","article-title":"Early Retinal Changes in Hunter Syndrome According to Spectral Domain Optical Coherence Tomography","volume":"30","author":"Kim","year":"2016","journal-title":"Korean J. Ophthalmol."},{"key":"10.1016\/bs.accb.2019.09.001_bb0390","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/13816810600677966","article-title":"Hunter Syndrome (MPS II-B): A Report of Bilateral Vitreous Floaters and Maculopathy","volume":"27","author":"Anawis","year":"2006","journal-title":"Ophthalmic Genet."},{"key":"10.1016\/bs.accb.2019.09.001_bb0395","doi-asserted-by":"crossref","first-page":"e1228","DOI":"10.1542\/peds.2008-0999","article-title":"Multidisciplinary Management of Hunter Syndrome","volume":"124","author":"Muenzer","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/bs.accb.2019.09.001_bb0400","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/00003446-198407000-00009","article-title":"Hearing Loss in Hunter's Syndrome\u2014Mucopolysaccharidosis II","volume":"5","author":"Peck","year":"1984","journal-title":"Ear Hear."},{"key":"10.1016\/bs.accb.2019.09.001_bb0405","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s10545-011-9378-5","article-title":"Hearing Loss in Patients with Mucopolysaccharidosis II: Data From HOS\u2014The Hunter Outcome Survey","volume":"35","author":"Keilmann","year":"2012","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/bs.accb.2019.09.001_bb0410","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ymgme.2014.02.003","article-title":"Assessment of Hearing Loss by Pure-tone Audiometry in Patients With Mucopolysaccharidoses","volume":"111","author":"Lin","year":"2014","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/bs.accb.2019.09.001_bb0415","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S0007-117X(72)80058-1","article-title":"Two Cases of Hunter's Syndrome\u2014The Anaesthetic and Operative Difficulties in Oral Surgery","volume":"10","author":"Hopkins","year":"1973","journal-title":"Br. J. Oral Surg."},{"key":"10.1016\/bs.accb.2019.09.001_bb0420","first-page":"98","article-title":"Hunter's Syndrome and Oral Manifestations: A Review","volume":"17","author":"Downs","year":"1995","journal-title":"Pediatr. Dent."},{"key":"10.1016\/bs.accb.2019.09.001_bb0425","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0165-5876(86)80034-9","article-title":"Upper Airway Obstruction in Hunter Syndrome","volume":"11","author":"Brama","year":"1986","journal-title":"Int. J. Pediatr. Otorhinolaryngol."},{"key":"10.1016\/bs.accb.2019.09.001_bb0430","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1288\/00005537-198703000-00005","article-title":"Hunter's Syndrome: A Study in Airway Obstruction","volume":"97","author":"Sasaki","year":"1987","journal-title":"Laryngoscope"},{"key":"10.1016\/bs.accb.2019.09.001_bb0435","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0165-5876(98)00063-9","article-title":"Acute Airway Obstruction in Hunter Syndrome","volume":"44","author":"Yoskovitch","year":"1998","journal-title":"Int. J. Pediatr. Otorhinolaryngol."},{"key":"10.1016\/bs.accb.2019.09.001_bb0440","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0165-5876(01)00417-7","article-title":"Disordered Breathing During Sleep in Patients With Mucopolysaccharidoses","volume":"58","author":"Leighton","year":"2001","journal-title":"Int. J. Pediatr. Otorhinolaryngol."},{"key":"10.1016\/bs.accb.2019.09.001_bb0445","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0165-5876(93)90096-L","article-title":"Tracheobronchomalacia in Hunter's Syndrome","volume":"26","author":"Morehead","year":"1993","journal-title":"Int. J. Pediatr. Otorhinolaryngol."},{"key":"10.1016\/bs.accb.2019.09.001_bb0450","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1177\/000348948509400508","article-title":"Airway Obstruction and Sleep Apnea in Hurler and Hunter Syndromes","volume":"94","author":"Shapiro","year":"1985","journal-title":"Ann. Otol. Rhinol. Laryngol."},{"key":"10.1016\/bs.accb.2019.09.001_bb0455","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1034\/j.1399-3003.1999.13e42.x","article-title":"Hunter\u2032s Syndrome and Associated Sleep Apnoea Cured by CPAP and Surgery","volume":"13","author":"Orliaguet","year":"1999","journal-title":"Eur. Respir. J."},{"key":"10.1016\/bs.accb.2019.09.001_bb0460","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/01.gim.0000232477.37660.fb","article-title":"A Phase II\/III Clinical Study of Enzyme Replacement Therapy With Idursulfase in Mucopolysaccharidosis II (Hunter Syndrome)","volume":"8","author":"Muenzer","year":"2006","journal-title":"Genet. Med."},{"key":"10.1016\/bs.accb.2019.09.001_bb0465","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ymgme.2006.09.001","article-title":"A Phase I\/II Clinical Trial of Enzyme Replacement Therapy in Mucopolysaccharidosis II (Hunter Syndrome)","volume":"90","author":"Muenzer","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/bs.accb.2019.09.001_bb0470","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ymgme.2009.08.006","article-title":"Japan Elaprase\u00ae Treatment (JET) Study: Idursulfase Enzyme Replacement Therapy in Adult Patients with Attenuated Hunter Syndrome (Mucopolysaccharidosis II, MPS II)","volume":"99","author":"Okuyama","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/bs.accb.2019.09.001_bb0475","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/GIM.0b013e3181fea459","article-title":"Long-term, Open-labeled Extension Study of Idursulfase in the Treatment of Hunter Syndrome","volume":"13","author":"Muenzer","year":"2011","journal-title":"Genet. Med."},{"key":"10.1016\/bs.accb.2019.09.001_bb0480","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/s004310050872","article-title":"Cardiovascular Changes in Children with Mucopolysaccharide Storage Diseases and Related Disorders\u2014Clinical and Echocardiographic Findings in 64 Patients","volume":"157","author":"Dangel","year":"1998","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/bs.accb.2019.09.001_bb0485","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/0002-9149(88)91325-2","article-title":"Echocardiographic Abnormalities in the Mucopolysaccharide Storage Diseases","volume":"61","author":"Gross","year":"1988","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/bs.accb.2019.09.001_bb0490","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000064674","article-title":"Cardiac Structural Involvement in Mucopolysaccharidoses","volume":"98","author":"Rigante","year":"2002","journal-title":"Cardiology"},{"key":"10.1016\/bs.accb.2019.09.001_bb0495","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/GIM.0b013e31817701e6","article-title":"Initial Report From the Hunter Outcome Survey","volume":"10","author":"Wraith","year":"2008","journal-title":"Genet. Med."},{"key":"10.1016\/bs.accb.2019.09.001_bb0500","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jpeds.2011.01.054","article-title":"Prevalence and Characterization of Cardiac Involvement in Hunter Syndrome","volume":"159","author":"Kampmann","year":"2011","journal-title":"J. Pediatr."},{"key":"10.1016\/bs.accb.2019.09.001_bb0505","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1016\/j.athoracsur.2004.06.021","article-title":"Mitral Valve Replacement for Mitral Stenosis Secondary to Hunter's Syndrome","volume":"80","author":"Bhattacharya","year":"2005","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/bs.accb.2019.09.001_bb0510","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S1054-8807(01)00099-0","article-title":"Left Ventricular Aneurysm, Aortic Valve Disease and Coronary Narrowing in a Patient With Hunter's Syndrome","volume":"11","author":"Kettles","year":"2002","journal-title":"Cardiovasc. Pathol."},{"key":"10.1016\/bs.accb.2019.09.001_bb0515","first-page":"1175","article-title":"Hunter's Syndrome. An Ultrastructural Study of an Autopsy Case","volume":"38","author":"Oda","year":"1988","journal-title":"Acta Pathol. Jpn."},{"key":"10.1016\/bs.accb.2019.09.001_bb0520","doi-asserted-by":"crossref","first-page":"e1258","DOI":"10.1542\/peds.2010-1274","article-title":"Natural Progression of Neurological Disease in Mucopolysaccharidosis Type II","volume":"127","author":"Holt","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/bs.accb.2019.09.001_bb0525","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/ana.410070418","article-title":"Myelopathy in Mucopolysaccharidosis Type II (Hunter Syndrome)","volume":"7","author":"Ballenger","year":"1980","journal-title":"Ann. Neurol."},{"key":"10.1016\/bs.accb.2019.09.001_bb0530","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1136\/jmg.31.3.257","article-title":"Neurogenic Bladder in Hunter's Syndrome","volume":"31","author":"Koyama","year":"1994","journal-title":"J. Med. Genet."},{"key":"10.1016\/bs.accb.2019.09.001_bb0535","first-page":"1402","article-title":"Cervical Myelopathy Secondary to Hunter Syndrome in an Adult","volume":"16","author":"Vinchon","year":"1995","journal-title":"Am. J. Neuroradiol."},{"key":"10.1016\/bs.accb.2019.09.001_bb0540","first-page":"93","article-title":"Hydrocephalus in Hunter Syndrome","volume":"34","author":"Van Aerde","year":"1981","journal-title":"Acta Paediatr. Belg."},{"key":"10.1016\/bs.accb.2019.09.001_bb0545","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s003810050049","article-title":"Cervical Decompression in Mild Mucopolysaccharidosis Type II (Hunter Syndrome)","volume":"13","author":"O'Brien","year":"1997","journal-title":"Child. Nerv. Syst."},{"key":"10.1016\/bs.accb.2019.09.001_bb0550","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S0959-437X(97)80153-0","article-title":"The Sulfatase Gene Family","volume":"7","author":"Parenti","year":"1997","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/bs.accb.2019.09.001_rf0555","doi-asserted-by":"crossref","first-page":"5736","DOI":"10.1002\/anie.200300632","article-title":"Sulfatases: Structure, Mechanism, Biological Activity, Inhibition, and Synthetic Utility","volume":"43","author":"Hanson","year":"2004","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/bs.accb.2019.09.001_rf9000","doi-asserted-by":"crossref","first-page":"15786","DOI":"10.1038\/ncomms15786","article-title":"Insights into Hunter Syndrome from the Structure of Iduronate-2-sulfatase","volume":"8","author":"Demydchuk","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/bs.accb.2019.09.001_bb0560","series-title":"Perspectives in Inherited Metabolic Diseases","first-page":"85","article-title":"The Active Site of the Enzyme Iduronate 2-Sulfate Sulfatase","volume":"vol. 7","author":"Daniele","year":"1987"},{"key":"10.1016\/bs.accb.2019.09.001_bb0565","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1042\/bj2710075","article-title":"Human Liver Iduronate-2-Sulphatase. Purification, Characterization and Catalytic Properties","volume":"271","author":"Bielicki","year":"1990","journal-title":"Biochem. J."},{"key":"10.1016\/bs.accb.2019.09.001_bb0570","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/(SICI)1521-1878(199806)20:6<505::AID-BIES9>3.0.CO;2-K","article-title":"A Novel Protein Modification Generating an Aldehyde Group in Sulfatases: Its Role in Catalysis and Disease","volume":"20","author":"von Figura","year":"1998","journal-title":"BioEssays"},{"key":"10.1016\/bs.accb.2019.09.001_bb0575","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1021\/cb500897w","article-title":"Formylglycine, A Post-Translationally Generated Residue With Unique Catalytic Capabilities and Biotechnology Applications","volume":"10","author":"Appel","year":"2015","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/bs.accb.2019.09.001_bb0580","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0969-2126(01)00609-8","article-title":"1.3 \u00c5 Structure of Arylsulfatase from Pseudomonas aeruginosa Establishes the Catalytic Mechanism of Sulfate Ester Cleavage in the Sulfatase Family","volume":"9","author":"Boltes","year":"2001","journal-title":"Structure"},{"key":"10.1016\/bs.accb.2019.09.001_bb0585","doi-asserted-by":"crossref","first-page":"7","DOI":"10.7705\/biomedica.v27i1.229","article-title":"Computational Prediction of the Tertiary Structure of the Human Iduronate 2-Sulfate Sulfatase","volume":"27","author":"S\u00e1enz","year":"2007","journal-title":"Biomedica"},{"key":"10.1016\/bs.accb.2019.09.001_bb0590","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s00431-012-1703-y","article-title":"Diagnosing Hunter Syndrome in Pediatric Practice: Practical Considerations and Common Pitfalls","volume":"171","author":"Burton","year":"2012","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/bs.accb.2019.09.001_bb0595","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1517\/21678707.2015.999666","article-title":"Diagnosis and Therapy Options in Mucopolysaccharidosis II (Hunter Syndrome)","volume":"3","author":"Giugliani","year":"2015","journal-title":"Expert Opin. Orphan Drugs"},{"key":"10.1016\/bs.accb.2019.09.001_bb0600","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0009-9120(87)80088-7","article-title":"Screening for Mucopolysaccharide Disorders With the Berry Spot Test","volume":"20","author":"Berry","year":"1987","journal-title":"Clin. Biochem."},{"key":"10.1016\/bs.accb.2019.09.001_bb0605","first-page":"21","article-title":"Colorimetric Method for the Determination of Sulfated Glycosaminoglycans","volume":"11","author":"Humbel","year":"1974","journal-title":"Rev. Roum. Biochim."},{"key":"10.1016\/bs.accb.2019.09.001_bb0610","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1093\/clinchem\/35.10.2074","article-title":"Diagnostic Test for Mucopolysaccharidosis. II. Rapid Quantification of Glycosaminoglycan in Urine Samples Collected on a Paper Matrix","volume":"35","author":"Whitley","year":"1989","journal-title":"Clin. Chem."},{"key":"10.1016\/bs.accb.2019.09.001_bb0615","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1093\/clinchem\/35.7.1472","article-title":"Dimethylmethylene Blue-Based Spectrophotometry of Glycosaminoglycans in Untreated Urine: A Rapid Screening Procedure for Mucopolysaccharidoses","volume":"35","author":"De Jong","year":"1989","journal-title":"Clin. Chem."},{"key":"10.1016\/bs.accb.2019.09.001_bb0620","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1373\/clinchem.2008.115410","article-title":"Tandem Mass Spectrometry for the Direct Assay of Lysosomal Enzymes in Dried Blood Spots: Application to Screening Newborns for Mucopolysaccharidosis I","volume":"54","author":"Blanchard","year":"2008","journal-title":"Clin. Chem."},{"key":"10.1016\/bs.accb.2019.09.001_bb0625","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.cca.2006.03.029","article-title":"Twelve Different Enzyme Assays on Dried-blood Filter Paper Samples for Detection of Patients with Selected Inherited Lysosomal Storage Diseases","volume":"372","author":"Civallero","year":"2006","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/bs.accb.2019.09.001_bb0630","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1373\/clinchem.2005.061838","article-title":"Detection of Mucopolysaccharidosis Type II by Measurement of Iduronate-2-Sulfatase in Dried Blood Spots and Plasma Samples","volume":"52","author":"Dean","year":"2006","journal-title":"Clin. Chem."},{"key":"10.1016\/bs.accb.2019.09.001_bb0635","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ymgme.2003.11.002","article-title":"Iduronate-2-Sulphatase Protein Detection in Plasma From Mucopolysaccharidosis Type II Patients","volume":"81","author":"Parkinson","year":"2004","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/bs.accb.2019.09.001_bb0640","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.cca.2006.01.001","article-title":"Detection of Hunter Syndrome (Mucopolysaccharidosis Type II) in Taiwanese: Biochemical and Linkage Studies of the Iduronate-2-Sulfatase Gene Defects in MPS II Patients and Carriers","volume":"369","author":"Lin","year":"2006","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/bs.accb.2019.09.001_bb0645","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0008-6215(00)87067-6","article-title":"An Assay for Iduronate Sulfatase (Hunter Corrective Factor)","volume":"37","author":"Lim","year":"1974","journal-title":"Carbohydr. Res."},{"key":"10.1016\/bs.accb.2019.09.001_bb0650","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0008-6215(00)85765-1","article-title":"\u03b1-L-Iduronidase, \u03b2-D-Glucuronidase, and 2-Sulfo-L-iduronate 2-Sulfatase: Preparation and Characterization of Radioactive Substrates From Heparin","volume":"69","author":"Hopwood","year":"1979","journal-title":"Carbohydr. Res."},{"key":"10.1016\/bs.accb.2019.09.001_bb0655","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1093\/clinchem\/47.12.2098","article-title":"Hurler-like Phenotype: Enzymatic Diagnosis in Dried Blood Spots on Filter Paper","volume":"47","author":"Chamoles","year":"2001","journal-title":"Clin. Chem."},{"key":"10.1016\/bs.accb.2019.09.001_bb0660","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1023\/A:1012763026526","article-title":"A Fluorimetric Enzyme Assay for the Diagnosis of MPS II (Hunter Disease)","volume":"24","author":"Voznyi","year":"2001","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/bs.accb.2019.09.001_bb0665","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/pd.457","article-title":"Prenatal Diagnosis of the Hunter Syndrome and the Introduction of a New Fluorimetric Enzyme Assay","volume":"22","author":"Keulemans","year":"2002","journal-title":"Prenatal Diagn."},{"key":"10.1016\/bs.accb.2019.09.001_bb0670","first-page":"89","article-title":"A Rapid Two-Step Iduronate-2-Sulfatatse Enzymatic Activity Assay for MPSII Pharmacokinetic Assessment","volume":"38","author":"Azadeh","year":"2018","journal-title":"JIMD Rep."},{"key":"10.1016\/bs.accb.2019.09.001_bb0675","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/j.cca.2011.06.015","article-title":"Rapid, Single-Step Assay for Hunter Syndrome in Dried Blood Spots Using Digital Microfluidics","volume":"412","author":"Sista","year":"2011","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/bs.accb.2019.09.001_bb0680","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1373\/clinchem.2006.077263","article-title":"Tandem Mass Spectrometry for the Direct Assay of Enzymes in Dried Blood Spots: Application to Newborn Screening for Mucopolysaccharidosis II (Hunter Disease)","volume":"53","author":"Wang","year":"2007","journal-title":"Clin. Chem."},{"key":"10.1016\/bs.accb.2019.09.001_bb0685","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.carres.2009.03.012","article-title":"Short Synthetic Sequence for 2-Sulfation of \u03b1-L-Iduronate Glycosides","volume":"344","author":"Blanchard","year":"2009","journal-title":"Carbohydr. Res."},{"key":"10.1016\/bs.accb.2019.09.001_bb0690","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1021\/ac102777s","article-title":"Tandem Mass Spectrometry for the Direct Assay of Lysosomal Enzymes in Dried Blood Spots: Application to Screening Newborns for Mucopolysaccharidosis II (Hunter Syndrome)","volume":"83","author":"Wolfe","year":"2011","journal-title":"Anal. Chem."},{"key":"10.1016\/bs.accb.2019.09.001_bb0695","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1373\/clinchem.2012.189936","article-title":"High-Throughput Assay of 9 Lysosomal Enzymes for Newborn Screening","volume":"59","author":"Spacil","year":"2013","journal-title":"Clin. Chem."},{"key":"10.1016\/bs.accb.2019.09.001_bb0700","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.clinbiochem.2015.08.016","article-title":"Direct Assay of Iduronate-2-Sulfatase for Hunter Disease Using UPLC-Tandem Mass Spectrometry and Fluorogenic Substrate","volume":"48","author":"Lee","year":"2015","journal-title":"Clin. Biochem."},{"key":"10.1016\/bs.accb.2019.09.001_bb0705","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1021\/ac5004135","article-title":"Improved Reagents for Newborn Screening of Mucopolysaccharidosis Types I, II, and VI by Tandem Mass Spectrometry","volume":"86","author":"Chennamaneni","year":"2014","journal-title":"Anal. Chem."},{"key":"10.1016\/bs.accb.2019.09.001_bb0710","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1373\/clinchem.2015.242560","article-title":"Tandem Mass Spectrometry Has a Larger Analytical Range than Fluorescence Assays of Lysosomal Enzymes: Application to Newborn Screening and Diagnosis of Mucopolysaccharidoses Types II, IVA, and VI","volume":"61","author":"Kumar","year":"2015","journal-title":"Clin. Chem."},{"key":"10.1016\/bs.accb.2019.09.001_bb0715","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ymgme.2009.10.001","article-title":"Validation of Disaccharide Compositions Derived From Dermatan Sulfate and Heparan Sulfate in Mucopolysaccharidoses and Mucolipidoses II and III by Tandem Mass Spectrometry","volume":"99","author":"Tomatsu","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/bs.accb.2019.09.001_bb0720","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ab.2007.05.016","article-title":"Analytical Method for the Determination of Disaccharides Derived From Keratan, Heparan, and Dermatan Sulfates in Human Serum and Plasma by High-Performance Liquid Chromatography\/Turbo Ionspray Ionization Tandem Mass Spectrometry","volume":"368","author":"Oguma","year":"2007","journal-title":"Anal. Biochem."},{"key":"10.1016\/bs.accb.2019.09.001_bb0725","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/glycob\/cwj072","article-title":"A Defect in Exodegradative Pathways Provides Insight Into Endodegradation of Heparan and Dermatan Sulfates","volume":"16","author":"Fuller","year":"2006","journal-title":"Glycobiology"},{"key":"10.1016\/bs.accb.2019.09.001_bb0730","doi-asserted-by":"crossref","first-page":"825","DOI":"10.4155\/bio-2018-0025","article-title":"A Novel LC-MS\/MS Assay to Quantify Dermatan Sulfate in Cerebrospinal Fluid as a Biomarker for Mucopolysaccharidosis II","volume":"10","author":"Pan","year":"2018","journal-title":"Bioanalysis"},{"key":"10.1016\/bs.accb.2019.09.001_bb0735","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ab.2010.04.002","article-title":"Determination of Urinary Oligosaccharides by High-Performance Liquid Chromatography\/Electrospray Ionization-Tandem Mass Spectrometry: Application to Hunter Syndrome","volume":"402","author":"Nielsen","year":"2010","journal-title":"Anal. Biochem."},{"key":"10.1016\/bs.accb.2019.09.001_bb0740","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/s41436-018-0136-z","article-title":"Disease and Subtype Specific Signatures Enable Precise Diagnosis of the Mucopolysaccharidoses","volume":"21","author":"Saville","year":"2019","journal-title":"Genet. Med."},{"key":"10.1016\/bs.accb.2019.09.001_bb0745","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nchembio.766","article-title":"Disease-Specific Non\u2013Reducing End Carbohydrate Biomarkers for Mucopolysaccharidoses","volume":"8","author":"Lawrence","year":"2012","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/bs.accb.2019.09.001_bb0750","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.ymgme.2012.09.024","article-title":"Heparan Sulfate and Dermatan Sulfate Derived Disaccharides are Sensitive Markers for Newborn Screening for Mucopolysaccharidoses Types I, II and III","volume":"107","author":"de Ruijter","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/bs.accb.2019.09.001_bb0755","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/nmeth0408-291","article-title":"Disaccharide Structure Code for the Easy Representation of Constituent Oligosaccharides From Glycosaminoglycans","volume":"5","author":"Lawrence","year":"2008","journal-title":"Nat. Methods"},{"key":"10.1016\/bs.accb.2019.09.001_bb0760","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/rcm.6861","article-title":"A Simple Method for Early Age Phenotype Confirmation Using Toe Tissue From a Mouse Model of MPS IIIA","volume":"28","author":"Trim","year":"2014","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/bs.accb.2019.09.001_bb0765","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ymgme.2010.09.003","article-title":"Efficient Analysis of Urinary Glycosaminoglycans by LC-MS\/MS in Mucopolysaccharidoses Type I, II and VI","volume":"102","author":"Auray-Blais","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/bs.accb.2019.09.001_bb0770","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.cca.2012.01.012","article-title":"An Improved Method for Glycosaminoglycan Analysis by LC-MS\/MS of Urine Samples Collected on Filter Paper","volume":"413","author":"Auray-Blais","year":"2012","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/bs.accb.2019.09.001_bb0775","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1373\/clinchem.2010.161141","article-title":"Analysis of Glycosaminoglycans in Cerebrospinal Fluid From Patients With Mucopolysaccharidoses by Isotope-Dilution Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry","volume":"57","author":"Zhang","year":"2011","journal-title":"Clin. Chem."},{"key":"10.1016\/bs.accb.2019.09.001_bb0780","doi-asserted-by":"crossref","first-page":"9243","DOI":"10.1021\/acs.analchem.5b01743","article-title":"Butanolysis Derivatization: Improved Sensitivity in LC-MS\/MS Quantitation of Heparan Sulfate in Urine From Mucopolysaccharidosis Patients","volume":"87","author":"Trim","year":"2015","journal-title":"Anal. Chem."},{"key":"10.1016\/bs.accb.2019.09.001_bb0785","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.cca.2018.11.001","article-title":"LC-MS\/MS Method for Simultaneous Quantification of Heparan Sulfate and Dermatan Sulfate in Urine by Butanolysis Derivatization","volume":"488","author":"Forni","year":"2019","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/bs.accb.2019.09.001_bb0790","doi-asserted-by":"crossref","first-page":"8791","DOI":"10.1039\/C8OB02225A","article-title":"Synthesis and Mass Spectrometric Analysis of Disaccharides From Methanolysis of Heparan Sulfate","volume":"16","author":"He","year":"2018","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/bs.accb.2019.09.001_bb0795","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1373\/clinchem.2014.225771","article-title":"Newborn Screening for Lysosomal Storage Diseases","volume":"61","author":"Gelb","year":"2015","journal-title":"Clin. Chem."},{"key":"10.1016\/bs.accb.2019.09.001_bb0800","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1517\/21678707.2013.780970","article-title":"Emerging Therapies and Therapeutic Concepts for Lysosomal Storage Diseases","volume":"1","author":"Kirkegaard","year":"2013","journal-title":"Expert Opin. Orphan Drugs"},{"key":"10.1016\/bs.accb.2019.09.001_bb0805","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1517\/21678707.2013.738182","article-title":"Evaluation of Idursulfase for the Treatment of Mucopolysaccharidosis II (Hunter Syndrome)","volume":"1","author":"Scarpa","year":"2013","journal-title":"Expert Opin. Orphan Drugs"},{"key":"10.1016\/bs.accb.2019.09.001_bb0810","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s10719-014-9523-0","article-title":"A Biochemical and Physicochemical Comparison of Two Recombinant Enzymes Used for Enzyme Replacement Therapies of Hunter Syndrome","volume":"31","author":"Chung","year":"2014","journal-title":"Glycoconjugate J."},{"key":"10.1016\/bs.accb.2019.09.001_bb0815","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/jhg.2016.133","article-title":"Comparative Study of Idursulfase Beta and Idursulfase In Vitro and In Vivo","volume":"62","author":"Kim","year":"2017","journal-title":"J. Hum. Genet."},{"key":"10.1016\/bs.accb.2019.09.001_bb0820","first-page":"311","article-title":"Review of the Use of Idursulfase in the Treatment of Mucopolysaccharidosis II","volume":"2","author":"Burrow","year":"2008","journal-title":"Biol. Targets Ther."},{"key":"10.1016\/bs.accb.2019.09.001_bb0825","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1750-1172-8-42","article-title":"Phase I\/II Clinical Trial of Enzyme Replacement Therapy With Idursulfase Beta in Patients With Mucopolysaccharidosis II (Hunter Syndrome)","volume":"8","author":"Sohn","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/bs.accb.2019.09.001_bb0830","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1080\/13543784.2017.1397130","article-title":"Phase I and II Clinical Trials for the Mucopolysaccharidoses","volume":"26","author":"Poswar","year":"2017","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"10.1016\/bs.accb.2019.09.001_bb0835","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1002\/bit.23118","article-title":"Expression in CHO Cells and Pharmacokinetics and Brain Uptake in the Rhesus Monkey of an IgG-Iduronate-2-Sulfatase Fusion Protein","volume":"108","author":"Lu","year":"2011","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/bs.accb.2019.09.001_bb0840","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1002\/bit.25289","article-title":"Insulin Receptor Antibody-Iduronate 2-Sulfatase Fusion Protein: Pharmacokinetics, Anti-drug Antibody, and Safety Pharmacology in Rhesus Monkeys","volume":"111","author":"Boado","year":"2014","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/bs.accb.2019.09.001_bb0845","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1016\/j.ymgme.2016.11.328","article-title":"Correction of Central Nervous System Deficits in the Mouse Model of Hunter Syndrome by Recombinant Iduronate 2-Sulfatase Crossing the Blood-Brain Barrier","volume":"120","author":"Sonoda","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/bs.accb.2019.09.001_bb0850","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.3390\/ijms17071065","article-title":"Less Is More: Substrate Reduction Therapy for Lysosomal Storage Disorders","volume":"17","author":"Coutinho","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/bs.accb.2019.09.001_bb0855","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/med.21429","article-title":"Drug-Mediated Regulation of Glycosaminoglycan Biosynthesis","volume":"37","author":"Ghiselli","year":"2017","journal-title":"Med. Res. Rev."},{"key":"10.1016\/bs.accb.2019.09.001_bb0860","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/j.1476-5381.2009.00565.x","article-title":"Genistein Reduces Glycosaminoglycan Levels in a Mouse Model of Mucopolysaccharidosis Type II","volume":"159","author":"Friso","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/bs.accb.2019.09.001_bb0865","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1002\/ajmg.a.34146","article-title":"Improvement in the Range of Joint Motion in Seven Patients with Mucopolysaccharidosis Type II During Experimental Gene Expression-Targeted Isoflavone Therapy (GET IT)","volume":"155","author":"Marucha","year":"2011","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/bs.accb.2019.09.001_bb0870","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s10545-011-9342-4","article-title":"Genistein Supplementation in Patients Affected by Sanfilippo Disease","volume":"34","author":"Delgadillo","year":"2011","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/bs.accb.2019.09.001_bb0875","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/ana.22643","article-title":"Genistein in Sanfilippo Disease: A Randomized Controlled Crossover Trial","volume":"71","author":"de Ruijter","year":"2012","journal-title":"Ann. Neurol."},{"key":"10.1016\/bs.accb.2019.09.001_bb0880","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3390\/diseases5010005","article-title":"Substrate Deprivation Therapy to Reduce Glycosaminoglycan Synthesis Improves Aspects of Neurological and Skeletal Pathology in MPS I Mice","volume":"5","author":"Derrick-Roberts","year":"2017","journal-title":"Diseases"},{"key":"10.1016\/bs.accb.2019.09.001_bb0885","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ymgme.2007.06.016","article-title":"Improvement in Behaviour After Substrate Deprivation Therapy with Rhodamine B in a Mouse Model of MPS IIIA","volume":"92","author":"Roberts","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/bs.accb.2019.09.001_bb0890","unstructured":"Masson, P.; Junien, J.-L. Use of Odiparcil in the Treatment of a Mucopolysacchardosis. US Patent 9,561,246 B2 2017."},{"key":"10.1016\/bs.accb.2019.09.001_bb0895","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1021\/acs.accounts.7b00289","article-title":"Synthetic Xylosides: Probing the Glycosaminoglycan Biosynthetic Machinery for Biomedical Applications","volume":"50","author":"Chua","year":"2017","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/bs.accb.2019.09.001_bb0900","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1111\/j.1538-7836.2006.02064.x","article-title":"A Comparison of the \u03b2-D-Xyloside, Odiparcil, to Warfarin in a Rat Model of Venous Thrombosis","volume":"4","author":"Toomey","year":"2006","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/bs.accb.2019.09.001_bb0905","unstructured":"ClinicalTrials.gov NCT03370653. A Study in MPS VI to Assess Safety and Efficacy of Odiparcil (iMProveS)."},{"key":"10.1016\/bs.accb.2019.09.001_bb0910","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1021\/jm301557k","article-title":"Pharmacological Chaperones as Therapeutics for Lysosomal Storage Diseases","volume":"56","author":"Boyd","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.accb.2019.09.001_bb0915","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/bs.accb.2016.08.002","article-title":"Carbohydrate-Processing Enzymes of the Lysosome: Diseases Caused by Misfolded Mutants and Sugar Mimetics as Correcting Pharmacological Chaperones","volume":"73","author":"St\u00fctz","year":"2016","journal-title":"Adv. Carbohydr. Chem. Biochem."},{"key":"10.1016\/bs.accb.2019.09.001_bb0920","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1038\/mt.2009.53","article-title":"The Pharmacological Chaperone N-butyldeoxynojirimycin Enhances Enzyme Replacement Therapy in Pompe Disease Fibroblasts","volume":"17","author":"Porto","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/bs.accb.2019.09.001_bb0925","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s40265-016-0607-y","article-title":"Migalastat: First Global Approval","volume":"76","author":"Markham","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/bs.accb.2019.09.001_bb0930","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ymgme.2017.12.428","article-title":"Chaperone Effect of Sulfated Disaccharide from Heparin on Mutant Iduronate-2-Sulfatase in Mucopolysaccharidosis Type II","volume":"123","author":"Hoshina","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/bs.accb.2019.09.001_bb0935","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.3762\/bjoc.11.282","article-title":"Exploring Architectures Displaying Multimeric Presentations of a Trihydroxypiperidine Iminosugar","volume":"11","author":"Matassini","year":"2015","journal-title":"Beilstein J. Org. Chem."},{"key":"10.1016\/bs.accb.2019.09.001_bb0940","doi-asserted-by":"crossref","first-page":"64847","DOI":"10.1039\/C6RA15806D","article-title":"Evidence for a Multivalent Effect in Inhibition of Sulfatases Involved in Lysosomal Storage Disorders (LSDs)","volume":"6","author":"D'Adamio","year":"2016","journal-title":"RSC Adv."},{"key":"10.1016\/bs.accb.2019.09.001_bb0945","doi-asserted-by":"crossref","first-page":"8604","DOI":"10.1039\/C8OB02587H","article-title":"Multimerization of DAB-1 Onto Au GNPs Affords New Potent and Selective N-Acetylgalactosamine-6-Sulfatase (GALNS) Inhibitors","volume":"16","author":"Matassini","year":"2018","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/bs.accb.2019.09.001_bb0950","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1586\/17446651.1.3.425","article-title":"Bone Marrow Transplantation for Lysosomal Storage Disorders","volume":"1","author":"Vellodi","year":"2006","journal-title":"Expert Rev. Endocrinol. Metab."},{"key":"10.1016\/bs.accb.2019.09.001_bb0955","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1023\/A:1005525931994","article-title":"Long-Term Follow-Up Following Bone Marrow Transplantation for Hunter Disease","volume":"22","author":"Vellodi","year":"1999","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/bs.accb.2019.09.001_bb0960","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0022-3476(96)70202-0","article-title":"Bone Marrow Transplantation in Hunter Syndrome","volume":"129","author":"McKinnis","year":"1996","journal-title":"J. Pediatr."},{"key":"10.1016\/bs.accb.2019.09.001_bb0965","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jpeds.2008.11.041","article-title":"Bone Marrow Transplantation in Children with Hunter Syndrome: Outcome After 7 to 17 Years","volume":"154","author":"Guffon","year":"2009","journal-title":"J. Pediatr."},{"key":"10.1016\/bs.accb.2019.09.001_bb0970","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ymgme.2017.12.434","article-title":"Gene Therapy for Mucopolysaccharidoses","volume":"123","author":"Sawamoto","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/bs.accb.2019.09.001_bb0975","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.86696","article-title":"CNS-Directed Gene Therapy for the Treatment of Neurologic and Somatic Mucopolysaccharidosis Type II (Hunter Syndrome)","volume":"1","author":"Motas","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/bs.accb.2019.09.001_bb0980","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1089\/hum.2016.101","article-title":"Delivery of an Adeno-Associated Virus Vector into Cerebrospinal Fluid Attenuates Central Nervous System Disease in Mucopolysaccharidosis Type II Mice","volume":"27","author":"Hinderer","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/bs.accb.2019.09.001_bb0985","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1089\/hum.2016.184","article-title":"Prevention of Neurocognitive Deficiency in Mucopolysaccharidosis Type II Mice by Central Nervous System-Directed, AAV9-Mediated Iduronate Sulfatase Gene Transfer","volume":"28","author":"Laoharawee","year":"2017","journal-title":"Hum. Gene Ther."}],"container-title":["Advances in Carbohydrate Chemistry and Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065231819300277?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065231819300277?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T19:15:32Z","timestamp":1758741332000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0065231819300277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"ISBN":["9780128209936"],"references-count":196,"URL":"https:\/\/doi.org\/10.1016\/bs.accb.2019.09.001","relation":{},"ISSN":["0065-2318"],"issn-type":[{"value":"0065-2318","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}